Evanson Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Evanson Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,068	Closed	-$12K	–	245
2019 Q3	$12K	Hold	1,068	–	–	﹤0.01%	236
2019 Q2	$30K	Hold	1,068	–	–	0.01%	238
2019 Q1	$29K	Hold	1,068	–	–	0.01%	238
2018 Q4	$30K	Hold	1,068	–	–	0.01%	225
2018 Q3	$82K	Hold	1,068	–	–	0.02%	234
2018 Q2	$111K	Hold	1,068	–	–	0.02%	244
2018 Q1	$135K	Hold	1,068	–	–	0.03%	244
2017 Q4	$69K	Hold	1,068	–	–	0.01%	246
2017 Q3	$63K	Hold	1,068	–	–	0.01%	232
2017 Q2	$68K	Hold	1,068	–	–	0.02%	222
2017 Q1	$84K	Hold	1,068	–	–	0.02%	220
2016 Q4	$50K	Hold	1,068	–	–	0.01%	215
2016 Q3	$77K	Hold	1,068	–	–	0.02%	200
2016 Q2	$68K	Hold	1,068	–	–	0.02%	198
2016 Q1	$248K	Buy	+1,068	New	+$259K	0.08%	161

Other funds holding ZVRA

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RFN

RDA Financial Network Akron, Iowa $459M AUM 24.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Evanson Asset Management's ZVRA Position: Q4 2019 in Review

Evanson Asset Management sold out of Zevra Therapeutics (ZVRA) in Q4 2019, closing a stake of 1,068 shares — an estimated $12K sold.

Evanson Asset Management first reported a position in ZVRA in Q1 2016 and held it in 15 quarters. The position peaked at $248K in Q1 2016. 27 funds tracked by Wall St. Rank hold ZVRA as of Q4 2019.

Evanson Asset Management reported no remaining Zevra Therapeutics position as of Q4 2019 after selling out during the quarter.
Evanson Asset Management sold 1,068 Zevra Therapeutics shares in Q4 2019, an estimated $12K.
Evanson Asset Management first reported a position in Zevra Therapeutics in Q1 2016 and held it in 15 quarters.
Evanson Asset Management's Zevra Therapeutics position peaked at $248K in Q1 2016.
27 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2019.

Based on Evanson Asset Management's 13F filing for Q4 2019, filed 13 Jan 2020.